Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis

NCT04250350 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04250350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04250350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
February 11, 2020
Completion date
June 22, 2022
Enrollment
206 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis